KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Return on Capital Employed (2019 - 2025)

Vir Biotechnology's Return on Capital Employed history spans 7 years, with the latest figure at 0.52% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 8.0% year-over-year to 0.52%; the TTM value through Dec 2025 reached 0.52%, down 8.0%, while the annual FY2025 figure was 0.43%, 5.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.52% at Vir Biotechnology, up from 0.53% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.93% in Q1 2022 and bottomed at 0.58% in Q1 2021.
  • The 5-year median for Return on Capital Employed is 0.3% (2021), against an average of 0.08%.
  • The largest annual shift saw Return on Capital Employed skyrocketed 150bps in 2022 before it crashed -107bps in 2023.
  • A 5-year view of Return on Capital Employed shows it stood at 0.34% in 2021, then rose by 10bps to 0.37% in 2022, then crashed by -202bps to 0.38% in 2023, then fell by -17bps to 0.44% in 2024, then decreased by -18bps to 0.52% in 2025.
  • Per Business Quant, the three most recent readings for VIR's Return on Capital Employed are 0.52% (Q4 2025), 0.53% (Q3 2025), and 0.44% (Q4 2024).